|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | indocyanine green-based fluorescence imaging in visceral and hepatobiliary and pancreatic surgery:State of the art and future directions显示文摘In recent years, the use of fluorescence-guided surgery(FGS) to treat benign and malignant visceral, hepatobiliary and pancreatic neoplasms has significantly increased. FGS relies on the fluorescence signal emitted by injected substances(fluorophores) after being illuminated by ad hoc laser sources to help guide the surgical procedure and provide the surgeon with real-time visualization of the fluorescent structures of interest that would be otherwise invisible. This review surveys and discusses the most common and emerging clinical applications of indocyanine green(ICG)-based fluorescence in visceral, hepatobiliary and pancreatic surgery. The analysis, findings, and discussion presented here rely on the authors' significant experience with this technique in their medical institutions, an up-to-date review of the most relevant articles published on this topic between 2014 and 2018, and lengthy discussions with key opinion leaders in the field during recent conferences and congresses. For each application, the benefits and limitations of this technique, as well as applicable future directions, are described. The imaging of fluorescence emitted by ICG is a simple, fast,relatively inexpensive, and harmless tool with numerous different applications in surgery for both neoplasms and benign pathologies of the visceral and hepatobiliary systems. The ever-increasing availability of visual systems that can utilize this tool will transform some of these applications into the standard of care in the near future. Further studies are needed to evaluate the strengths and weaknesses of each application of ICG-based fluorescence imaging in abdominal surgery. | Gian Luca Baiocchi Michele Diana Luigi Boni | 2018 | World Journal of Gastroenterology2018，24，27： | 19 |
| 2 | MR-Guided High-Intensity Focused Ultrasound: Current Status of an Emerging Technology显示文摘 | Alessandro Napoli Michele Anzidei Federica Ciolina Eugenio Marotta Beatrice Cavallo Marincola Giulia Brachetti Luisa Mare Gaia Cartocci Fabrizio Boni Vincenzo Noce Luca Bertaccini Carlo Catalano | 2013 | CardioVascular and Interventional Radiology2013，，5： | 2 |
| 3 | combined bovine herpesvirus 1 gB-gC DNA vaccine induces immune response in mice显示文摘 | CASELLI E BONI M DI LUCA D | 2005 | Comp Immunol Microbiol Infect Dis2005，28，2： | 1 |
| 4 | First-line chemo- therapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference? 显示文摘 | TISEO M ARDIZZONI A BONI Luca | 2014 | J Thorac Oncol2014，9，11： | 1 |
| 5 | A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice显示文摘 | Caselli E Boni M Luca D | 2005 | Comparative Immunology Microbiology& Infectious Diseases2005，28，： | 1 |
| 6 | Effects of l -carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l -Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial显示文摘 | Sabino Iliceto Domenico Scrutinio Paolo Bruzzi Gaetano D’Ambrosio Luca Boni Matteo Di Biase Giuseppina Biasco Paul G. Hugenholtz Paolo Rizzon | 1995 | Journal of the American College of Cardiology1995，，2： | 1 |
| 7 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib显示文摘AIM:To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma(HCC)in patients with established cirrhosis.METHODS:From October 2009 to July 2012 patients with an established diagnosis of cirrhosis and HCC treated with sorafenib were consecutively enrolled.According to the Barcelona Clinic Liver Cancer(BCLC)classification,patients were in the advanced stage(BCLC-C)or in the intermediate stage(BCLC-B)but unfit or unresponsive to other therapeutic strategies.Treatment was evaluated performing a 4-phase computed tomography or magnetic resonance imaging scan every 2-3 mo,and analyzed according to the modified Response Evaluation Criteria in Solid Tumors.Sorafenib was administered at 800 mg/d,until radiological progression or occurrence of unacceptable adverse events(AEs).Univariate and multivariate analyses identified predictors of 16-wk clinical benefit and overall survival.RESULTS:Forty-four patients were enrolled,15 had intermediate HCC and 14 a Child-Pugh score of B7.AEs caused treatment interruption in 19 patients(43%),and median treatment duration was shorter in this subset(5 wk vs 19 wk,P<0.001)and in the BCLC-C subgroup(13 wk vs 40 wk,P=0.015).No significant differences in the reason for treatment interruption or in treatment duration were found comparing patients in Child-Pugh class A vs B or in patients older or younger than 70 years.After 16 wk of treatment,18 patients(41%)had stable disease or partial response.Patients with viral infection or BCLC-C were at higher risk of disease progression.ECOG,extrahepatic spread,macrovascular invasion,alpha-fetoprotein or alkaline phosphatase levels at admission were independent predictors of overall survival.CONCLUSION:In patients with cirrhosis and HCC treated with sorafenib,AEs are a common cause of early treatment withdrawal.Vascular invasion and extrahepatic spread condition early response to treatment and survival.Baseline biochemical parameters may be helpful to identify patients at higher risk of shorter overall survival. | Andrea L Inghilesi Donatella Gallori Lorenzo Antonuzzo Paolo Forte Daniela Tomcikova Umberto Arena Stefano Colagrande Silvia Pradella Bernardo Fani Elena Gianni Luca Boni Giacomo Laffi Francesco Di Costanzo Fabio Marra | 2014 | World Journal of Gastroenterology2014，20，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员